IGEM Therapeutics has announced the appointment of Dr David Chiswell as its new non-executive chairman, effective immediately.
Having recently stepped down from his position as Kymab’s CEO, Dr Chiswell brings more than 30 years’ experience in the biotechnology industry to IGEM’s Board. He is a past chairman of the UK BioIndustry Association and his contributions to the field were recognised in 2006 when he was awarded an OBE for services to the biotechnology industry.
Commenting on the appointment, Dr Tim Wilson, chief executive officer of IGEM, said:
“We are thrilled to have Dr Chiswell joining our Board of Directors. His in-depth knowledge of therapeutic antibody discovery and development as well as his extensive experience leading the growth of early-stage biotechnology companies will make him an invaluable member of our team. I look forward to working with him and the rest of our Board. Additionally, I would like to thank Peter for Chairing the company with distinction over the past two years.”